- Xenon's partner Teva Pharmaceutical Industries Ltd. is conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial for TV-45070 in patients with post-herpetic neuralgia, with results initially expected in the second half of 201, but got delayed to 2H 2017.
Catalyst
Slingshot members are tracking this event:
Phase 2 data of TV-45070 for Postherpetic neuralgia due 1H 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2017
Occurred Source:
http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2283350
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b Data, Tv-45070, Postherpetic Euralgia, 2h 2016
